Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World Most cancers Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2021;71:209–49.
Teo MY, Rathkopf DE, Kantoff P. Remedy of superior prostate most cancers. Annu Rev Med. 2019;70:479–99.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate most cancers (CRPC). Transl Androl Urol. 2015;4:365–80.
Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, et al. SETD2 restricts prostate most cancers metastasis by integrating EZH2 and AMPK signaling pathways. Most cancers Cell. 2020;38:350–65.e357.
Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going past Polycomb: EZH2 capabilities in prostate most cancers. Oncogene. 2021;40:5788–98.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational panorama of deadly castration-resistant prostate most cancers. Nature. 2012;487:239–43.
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene results in metastatic prostate most cancers. Most cancers Cell. 2003;4:209–21.
Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The position of GATA2 in deadly prostate most cancers aggressiveness. Nat Rev Urol. 2017;14:38–48.
Bohm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM. A job for GATA-2 in transition to an aggressive phenotype in prostate most cancers by modulation of key androgen-regulated genes. Oncogene. 2009;28:3847–56.
Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, et al. MAPK4 promotes prostate most cancers by concerted activation of androgen receptor and AKT. J Clin Investig. 2021;131:e135465.
Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, et al. Three-tiered position of the pioneer issue GATA2 in selling androgen-dependent gene expression in prostate most cancers. Nucleic Acids Res. 2014;42:3607–22.
He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complicated. Proc Natl Acad Sci USA. 2014;111:18261–6.
Chiang YT, Wang Ok, Fazli L, Qi RZ, Gleave ME, Collins CC, et al. GATA2 as a possible metastasis-driving gene in prostate most cancers. Oncotarget. 2014;5:451–61.
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, et al. A targetable GATA2-IGF2 axis confers aggressiveness in deadly prostate most cancers. Most cancers Cell. 2015;27:223–39.
Kaochar S, Rusin A, Foley C, Rajapakshe Ok, Robertson M, Skapura D, et al. Inhibition of GATA2 in prostate most cancers by a clinically out there small molecule. Endocr Relat Most cancers. 2021;29:15–31.
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Sort I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–14.
Borden EC. Interferons alpha and beta in most cancers: therapeutic alternatives from new insights. Nat Rev Drug Discov. 2019;18:219–34.
Khodarev NN. Intracellular RNA sensing in mammalian cells: position in stress response and most cancers therapies. Int Rev Cell Mol Biol. 2019;344:31–89.
Solar L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that prompts the sort I interferon pathway. Science. 2013;339:786–91.
Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537–51.
Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, et al. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent purposeful actions in vitro and in vivo. J Immunol. 2008;180:1462–70.
Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, et al. Sort I interferons defend T cells in opposition to NK cell assault mediated by the activating receptor NCR1. Immunity. 2014;40:961–73.
Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, et al. Sort I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity. 2014;40:949–60.
Novikov A, Cardone M, Thompson R, Shenderov Ok, Kirschman KD, Mayer-Barber KD, et al. Mycobacterium tuberculosis triggers host kind I IFN signaling to manage IL-1beta manufacturing in human macrophages. J Immunol. 2011;187:2540–7.
Spaapen RM, Leung MY, Fuertes MB, Kline JP, Zhang L, Zheng Y, et al. Therapeutic exercise of high-dose intratumoral IFN-beta requires direct impact on the tumor vasculature. J Immunol. 2014;193:4254–60.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: previous, present and future influence on biomedicine. Nat Rev Drug Discov. 2007;6:975–90.
Borden EC, Parkinson D. A perspective on the scientific effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25:3–8.
An X, Zhu Y, Zheng T, Wang G, Zhang M, Li J, et al. An evaluation of the expression and affiliation with immune cell infiltration of the cGAS/STING pathway in pan-cancer. Mol Ther Nucleic Acids. 2019;14:80–9.
Chin EN, Sulpizio A, Lairson LL. Focusing on STING to advertise antitumor immunity. Developments Cell Biol. 2023;33:189–203.
Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Make investments. 2019;129:4850–62.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced kind I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52.
Newman AM, Liu CL, Inexperienced MR, Gentles AJ, Feng W, Xu Y, et al. Sturdy enumeration of cell subsets from tissue expression profiles. Nat Strategies. 2015;12:453–7.
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the inhabitants abundance of tissue-infiltrating immune and stromal cell populations utilizing gene expression. Genome Biol. 2016;17:218.
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for evaluation of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509–14.
Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue mobile heterogeneity panorama. Genome Biol. 2017;18:220.
Ablasser A, Hur S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat Immunol. 2020;21:17–29.
Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical community of transcription components governs androgen receptor-dependent prostate most cancers progress. Mol Cell. 2007;27:380–92.
Zhao JC, Fong KW, Jin HJ, Yang YA, Kim J, Yu J. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene. 2016;35:4335–44.
Li S, Wan C, Zheng R, Fan J, Dong X, Meyer CA, et al. Cistrome-GO: an online server for purposeful enrichment evaluation of transcription issue ChIP-seq peaks. Nucleic Acids Res. 2019;47:W206–11.
Shuai Ok, Liu B. Regulation of gene-activation pathways by PIAS proteins within the immune system. Nat Rev Immunol. 2005;5:593–605.
Liu B, Tahk S, Yee KM, Fan G, Shuai Ok. The ligase PIAS1 restricts pure regulatory T cell differentiation by epigenetic repression. Science. 2010;330:521–5.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate most cancers. N Engl J Med. 2010;363:411–22.
Powles T, Yuen KC, Gillessen S, Kadel EE third, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate most cancers: a randomized section 3 trial. Nat Med. 2022;28:144–53.
Imamura Y, Sadar MD. Androgen receptor focused therapies in castration-resistant prostate most cancers: Bench to clinic. Int J Urol. 2016;23:654–65.
Solar BL. Immunotherapy in therapy of metastatic prostate most cancers: An strategy to bypass immunosuppressive tumor microenvironment. Prostate. 2021;81:1125–34.
Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, et al. Affiliation of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and scientific outcomes in prostate most cancers. Mod Pathol. 2018;31:1539–52.
Laccetti AL, Subudhi SK. Immunotherapy for metastatic prostate most cancers: immuno-cold or the tip of the iceberg? Curr Opin Urol. 2017;27:566–71.
Wang C, Zhang Y, Gao WQ. The evolving position of immune cells in prostate most cancers. Most cancers Lett. 2022;525:9–21.
Guillot B, Portales P, Thanh AD, Merlet S, Dereure O, Clot J, et al. The expression of cytotoxic mediators is altered in mononuclear cells of sufferers with melanoma and elevated by interferon-alpha therapy. Br J Dermatol. 2005;152:690–6.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: position of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237–49.
Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no impact on disease-free survival in prostate most cancers sufferers. Clin Most cancers Res. 2011;17:1571–81.
Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide doesn’t enhance total survival in prostate most cancers. Cell Rep Med. 2022;3:100613.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq information with DESeq2. Genome Biol. 2014;15:550.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative evaluation of complicated most cancers genomics and scientific profiles utilizing the cBioPortal. Sci Sign. 2013;6:pl1.
